NO20033593L - Kinazoliner som MMP-13 inhibitorer - Google Patents
Kinazoliner som MMP-13 inhibitorerInfo
- Publication number
- NO20033593L NO20033593L NO20033593A NO20033593A NO20033593L NO 20033593 L NO20033593 L NO 20033593L NO 20033593 A NO20033593 A NO 20033593A NO 20033593 A NO20033593 A NO 20033593A NO 20033593 L NO20033593 L NO 20033593L
- Authority
- NO
- Norway
- Prior art keywords
- quinazolines
- mmp
- inhibitors
- Prior art date
Links
- 102100027995 Collagenase 3 Human genes 0.000 title 1
- 108050005238 Collagenase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003246 quinazolines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26866101P | 2001-02-14 | 2001-02-14 | |
PCT/EP2002/001979 WO2002064572A1 (en) | 2001-02-14 | 2002-02-11 | Quinazolines as mmp-13 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20033593L true NO20033593L (no) | 2003-08-13 |
NO20033593D0 NO20033593D0 (no) | 2003-08-13 |
Family
ID=23023949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20033593A NO20033593D0 (no) | 2001-02-14 | 2003-08-13 | Kinazoliner som MMP-13 inhibitorer |
Country Status (30)
Country | Link |
---|---|
US (1) | US20020193377A1 (hu) |
EP (1) | EP1368324A1 (hu) |
JP (1) | JP2004523546A (hu) |
KR (1) | KR20030074827A (hu) |
CN (1) | CN1537105A (hu) |
AP (1) | AP2003002841A0 (hu) |
AR (1) | AR032676A1 (hu) |
BG (1) | BG108091A (hu) |
BR (1) | BR0207268A (hu) |
CA (1) | CA2437122A1 (hu) |
CZ (1) | CZ20032142A3 (hu) |
EA (1) | EA200300792A1 (hu) |
EC (1) | ECSP034730A (hu) |
EE (1) | EE200300384A (hu) |
HU (1) | HUP0303164A2 (hu) |
IL (1) | IL157109A0 (hu) |
IS (1) | IS6886A (hu) |
MA (1) | MA26994A1 (hu) |
MX (1) | MXPA03007248A (hu) |
NO (1) | NO20033593D0 (hu) |
OA (1) | OA12550A (hu) |
PA (1) | PA8539401A1 (hu) |
PE (1) | PE20021005A1 (hu) |
PL (1) | PL367396A1 (hu) |
SK (1) | SK10012003A3 (hu) |
SV (1) | SV2003000876A (hu) |
TN (1) | TNSN03045A1 (hu) |
UY (1) | UY27173A1 (hu) |
WO (1) | WO2002064572A1 (hu) |
ZA (1) | ZA200306008B (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
JP4164028B2 (ja) | 2001-10-12 | 2008-10-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルキンマトリックスメタロプロテイナーゼ阻害剤 |
WO2003076416A1 (en) * | 2002-03-08 | 2003-09-18 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
CA2492379A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
WO2004006931A2 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
BR0312943A (pt) * | 2002-07-17 | 2005-07-12 | Warner Lambert Co | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
EP1537090A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
ES2283851T3 (es) | 2002-08-13 | 2007-11-01 | Warner-Lambert Company Llc | Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
JP2006501215A (ja) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
EP1530472A1 (en) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
JP4859460B2 (ja) * | 2002-12-06 | 2012-01-25 | アフィニウム ファーマシューティカルズ, インク. | ヘテロ環化合物、その製造方法および治療におけるその使用 |
AU2003300114B9 (en) * | 2002-12-31 | 2009-11-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
CA2536313A1 (en) * | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
NZ550796A (en) * | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
CA2602609A1 (en) | 2005-03-16 | 2006-09-21 | Junichi Yokotani | Novel anthranilic acid derivative or salt thereof |
CA2658506C (en) | 2006-07-20 | 2016-01-26 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab 1 inhibitors |
WO2008098374A1 (en) | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
BRPI0808422A2 (pt) * | 2007-03-06 | 2015-06-23 | Novartis Ag | Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009155001A2 (en) | 2008-05-27 | 2009-12-23 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
WO2010132815A1 (en) | 2009-05-15 | 2010-11-18 | The Research Foundation Of State University Of New York | Curcumin analogues as zinc chelators and their uses |
EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
WO2013019682A1 (en) * | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
FR2991578B1 (fr) * | 2012-06-06 | 2019-12-27 | L'oreal | Composes pour application anti-age et peau seche |
WO2013190384A1 (en) | 2012-06-19 | 2013-12-27 | Affinium Pharmaceuticals, Inc. | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
ITMI20130646A1 (it) * | 2013-04-19 | 2014-10-20 | Univ Bologna Alma Mater | Composti chinazolindionici con attività inibente sulle sirtuine |
CN103664767A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种2,6-吡啶二甲酸的制备方法 |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3180345B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders |
EP3180337B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives |
EP3180342B1 (en) * | 2014-08-11 | 2019-06-26 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
EP3192791A4 (en) * | 2014-09-11 | 2018-03-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
MX2018010254A (es) | 2016-02-26 | 2018-12-19 | Debiopharm Int Sa | Medicamento para el tratamiento de infecciones de pie diabetico. |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
CN111116494B (zh) * | 2019-12-31 | 2022-08-16 | 江苏中旗科技股份有限公司 | 一类含喹唑啉二酮结构的酰胺类化合物、其制备方法与应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU119879A1 (ru) * | 1958-10-21 | 1958-11-30 | В.М. Нестеров | Способ получени 1,3-диметил-4-имино-5,-изонитрозоурацила |
CA764962A (en) * | 1962-03-22 | 1967-08-08 | Ohnacker Gerhard | Pyrido-pyrimidines |
CA762455A (en) * | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
DK408574A (hu) * | 1973-09-06 | 1975-05-05 | Ciba Geigy Ag | |
DE3502590A1 (de) * | 1985-01-26 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-alkoxy-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
DE3502742A1 (de) * | 1985-01-28 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-oxo-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
GB9214053D0 (en) * | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
ATE181832T1 (de) * | 1993-04-23 | 1999-07-15 | Hoechst Ag | Pyrido-pyrimidindione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US5281602A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetrahydro-pyrido[4,3-D]pyrimidin-4(3H)-ones |
ATE198593T1 (de) * | 1995-08-02 | 2001-01-15 | Uriach & Cia Sa J | Pyrimidonderivate mit antifungaler wirkung |
ZA974030B (en) * | 1996-05-15 | 1998-02-19 | Bayer Ag | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids. |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
AU4429799A (en) * | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
US20030114666A1 (en) * | 2001-06-19 | 2003-06-19 | Ellsworth Edmund Lee | Antibacterial agents |
EP1513820A4 (en) * | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003281168A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
WO2004006914A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
WO2004006931A2 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
WO2004014377A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
EP1530472A1 (en) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
AU2003253149A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
EP1537090A1 (en) * | 2002-08-13 | 2005-06-08 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
AU2003250466A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
US7439249B2 (en) * | 2002-12-31 | 2008-10-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
WO2004112793A1 (en) * | 2003-05-23 | 2004-12-29 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
WO2005028478A1 (en) * | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Aza-quinolinol phosphonate integrase inhibitor compounds |
-
2002
- 2002-02-08 PA PA20028539401A patent/PA8539401A1/es unknown
- 2002-02-11 KR KR10-2003-7010659A patent/KR20030074827A/ko not_active Application Discontinuation
- 2002-02-11 AP APAP/P/2003/002841A patent/AP2003002841A0/en unknown
- 2002-02-11 IL IL15710902A patent/IL157109A0/xx unknown
- 2002-02-11 MX MXPA03007248A patent/MXPA03007248A/es unknown
- 2002-02-11 CZ CZ20032142A patent/CZ20032142A3/cs unknown
- 2002-02-11 BR BR0207268-8A patent/BR0207268A/pt not_active IP Right Cessation
- 2002-02-11 HU HU0303164A patent/HUP0303164A2/hu unknown
- 2002-02-11 JP JP2002564505A patent/JP2004523546A/ja not_active Abandoned
- 2002-02-11 SK SK1001-2003A patent/SK10012003A3/sk unknown
- 2002-02-11 EP EP02722137A patent/EP1368324A1/en not_active Withdrawn
- 2002-02-11 PL PL02367396A patent/PL367396A1/xx not_active Application Discontinuation
- 2002-02-11 CA CA002437122A patent/CA2437122A1/en not_active Abandoned
- 2002-02-11 CN CNA028050142A patent/CN1537105A/zh active Pending
- 2002-02-11 EE EEP200300384A patent/EE200300384A/xx unknown
- 2002-02-11 OA OA1200300200A patent/OA12550A/en unknown
- 2002-02-11 WO PCT/EP2002/001979 patent/WO2002064572A1/en not_active Application Discontinuation
- 2002-02-11 EA EA200300792A patent/EA200300792A1/ru unknown
- 2002-02-13 SV SV2002000876A patent/SV2003000876A/es not_active Application Discontinuation
- 2002-02-13 US US10/075,954 patent/US20020193377A1/en not_active Abandoned
- 2002-02-13 PE PE2002000118A patent/PE20021005A1/es not_active Application Discontinuation
- 2002-02-13 UY UY27173A patent/UY27173A1/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100470A patent/AR032676A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/EP2002/001979A patent/TNSN03045A1/en unknown
- 2003-07-24 IS IS6886A patent/IS6886A/is unknown
- 2003-08-04 ZA ZA2003/06008A patent/ZA200306008B/en unknown
- 2003-08-12 MA MA27274A patent/MA26994A1/fr unknown
- 2003-08-13 EC EC2003004730A patent/ECSP034730A/es unknown
- 2003-08-13 NO NO20033593A patent/NO20033593D0/no not_active Application Discontinuation
- 2003-08-13 BG BG108091A patent/BG108091A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0303164A2 (hu) | 2004-01-28 |
BR0207268A (pt) | 2005-03-15 |
EE200300384A (et) | 2003-12-15 |
ZA200306008B (en) | 2005-01-26 |
UY27173A1 (es) | 2002-09-30 |
PE20021005A1 (es) | 2002-11-27 |
SV2003000876A (es) | 2003-08-19 |
MA26994A1 (fr) | 2004-12-20 |
NO20033593D0 (no) | 2003-08-13 |
IS6886A (is) | 2003-07-24 |
KR20030074827A (ko) | 2003-09-19 |
CA2437122A1 (en) | 2002-08-22 |
OA12550A (en) | 2006-06-05 |
AR032676A1 (es) | 2003-11-19 |
TNSN03045A1 (en) | 2005-12-23 |
BG108091A (en) | 2004-12-30 |
PA8539401A1 (es) | 2002-10-28 |
MXPA03007248A (es) | 2005-02-14 |
CZ20032142A3 (cs) | 2004-12-15 |
WO2002064572A1 (en) | 2002-08-22 |
PL367396A1 (en) | 2005-02-21 |
JP2004523546A (ja) | 2004-08-05 |
AP2003002841A0 (en) | 2003-09-30 |
CN1537105A (zh) | 2004-10-13 |
US20020193377A1 (en) | 2002-12-19 |
EA200300792A1 (ru) | 2004-02-26 |
SK10012003A3 (sk) | 2004-09-08 |
ECSP034730A (es) | 2003-12-01 |
IL157109A0 (en) | 2004-02-08 |
EP1368324A1 (en) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20033593D0 (no) | Kinazoliner som MMP-13 inhibitorer | |
CY2015028I2 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
DE60234125D1 (de) | E inhibitoren | |
NO20034045L (no) | Metallproteinase-inhibitorer | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
ATE420640T1 (de) | Fab-i-inhibitoren | |
PT1370553E (pt) | Inibidores de rhoquinase | |
IS7362A (is) | Kínasólín efnasambönd | |
NO20042279L (no) | Kinazolinderivater som antitumormidler | |
NO20042288L (no) | Kinazolinderivater som antitumormidler | |
IS6971A (is) | Ný efnasambönd | |
ATE286049T1 (de) | Pyridazinonaldose reductase inhibitoren | |
NO20034032D0 (no) | Metallproteinase-inhibitorer | |
NO20034949L (no) | Sulfonamider | |
NO20014597D0 (no) | Fremgangsmåte | |
NO20035573L (no) | Kinazolinderivater | |
ITMI20010954A0 (it) | Procedimento di iodurazione | |
DE60201464D1 (de) | Halbleiterlaser | |
DE50212755D1 (de) | Bohrfutter | |
SE0100694D0 (sv) | DHFR inhibitors | |
ATE270267T1 (de) | Scyphostatin-analoga als smase-inhibitoren | |
SE0100199D0 (sv) | New formulation | |
SE0101659D0 (sv) | New compounds | |
SE0101958D0 (sv) | New compounds | |
SE0102056D0 (sv) | New Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |